Marinomed Biotech (MARI) Health Care Conference summary

Business model and technology

• Focuses on solubilizing poorly soluble drugs using proprietary Marinosolve technology, enabling higher bioavailability and lower doses for mucosal delivery.

• Generates revenue through upfront payments, milestones, royalties, and service fees from both in-house and client-sponsored projects.

• Offers unique research services under the Solve for You brand, expanding its global client base, especially in Europe.

• Recently restructured financially, posting profits from asset sales and reducing debt by 70%.

• Maintains a lean business model with experienced management and long-term investors.

Pipeline and product development

• Lead asset Budesolf, a nasal spray for severe allergic rhinitis, completed phase 3 trials and targets a market with unmet needs.

• Budesolf offers a preservative-free, fast-acting, low-dose solution with patent protection, aiming to disrupt the nasal steroid market.

• Market transformation strategy involves partnerships for marketing, regulatory, and production expertise tailored to regional OTC/Rx differences.

• Regulatory progress includes a bridging pharmacokinetic study to address formulation changes, with Swiss Medic providing a clear path forward.

• Commercial partnership for Switzerland established, with plans to use it as a reference for further international expansion.

Financial outlook and partnerships

• Divested Carragelose business, receiving €5M upfront and eligible for up to €10M each in financial and operational earnouts, capped at €15M.

• Earnout payments are based on EBIT and operational milestones, with timelines extending into 2026 and beyond.

• Transitional service agreement and new product development projects with the buyer provide ongoing revenue streams.

• Financial restructuring and asset sales have improved financial stability and planning.

• Ongoing efforts to secure additional commercial partnerships in key global markets.